- Genetic predisposition in nonalcoholic fatty liver disease
-
Sookoian S, Pirola CJ
- KMID: 2412107
- Clin Mol Hepatol.
- 2017 Mar;23(1):1-12.
- doi: 10.3350/cmh.2016.0109
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease whose prevalence has reached global epidemic proportions. Although the disease is relatively benign in the early stages, when... -
- CITED
-
- Close
- SHARE
-
- Close
- The gene expression signature of metabolic dysfunction- associated steatotic liver disease from a multiomics perspective
-
Pirola CJ, Sookoian S
- KMID: 2554424
- Clin Mol Hepatol.
- 2024 Apr;30(2):174-176.
- doi: 10.3350/cmh.2024.0082
-
- CITED
-
- Close
- SHARE
-
- Close
- Personalized medicine in nonalcoholic fatty liver disease
-
Pirola CJ, Sookoian S
- KMID: 2534359
- Clin Mol Hepatol.
- 2022 Oct;28(4):935-938.
- doi: 10.3350/cmh.2022.0175
-
- CITED
-
- Close
- SHARE
-
- Close
- Repurposing drugs to target nonalcoholic steatohepatitis: Auranofin, a gold-organic molecule complex for the treatment of a specifc complex trait
-
Pirola CJ, Sookoian S
- KMID: 2534345
- Clin Mol Hepatol.
- 2022 Oct;28(4):806-809.
- doi: 10.3350/cmh.2022.0208
-
- CITED
-
- Close
- SHARE
-
- Close
- Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response
-
Sookoian S, Pirola CJ
- KMID: 2539800
- Clin Mol Hepatol.
- 2023 Feb;29(Suppl):S184-S195.
- doi: 10.3350/cmh.2022.0318
The knowledge on the genetic component of non-alcoholic fatty liver disease (NAFLD) has grown exponentially over the last 10 to 15 years. This review summarizes the current evidence and the... -
- CITED
-
- Close
- SHARE
-
- Close
- Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology
-
Sookoian S, Pirola CJ
- KMID: 2507963
- Clin Mol Hepatol.
- 2020 Oct;26(4):461-475.
- doi: 10.3350/cmh.2020.0136
Despite more than two decades of extensive research focusing on nonalcoholic fatty liver disease (NAFLD), no approved therapy for steatohepatitis—the severe histological form of the disease—presently exists. More importantly, new... -
- CITED
-
- Close
- SHARE
-
- Close
- Metabolic dysfunction-associated steatotic liver disease exhibits sex-specific microbial heterogeneity within intestinal compartments
-
Pirola CJ, Landa MS, Schuman M, García SI, Salatino A, Sookoian S
- KMID: 2563419
- Clin Mol Hepatol.
- 2025 Jan;31(1):179-195.
- doi: 10.3350/cmh.2024.0359
Background/Aims: Evidence suggests that the gastrointestinal microbiome plays a significant role in the biology of metabolic dysfunction-associated steatotic liver disease (MASLD). However, it remains unclear whether disparities in the gut... -
- CITED
-
- Close
- SHARE
-
- Close
